by admin | Nov 30, 2017 | Press Releases
The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer induced a 90% recovery of gut microbiome diversity. These promising results could open new avenues for treating several conditions in the...
by admin | Jul 20, 2017 | Press Releases
Within thirty months of its creation, Maat Pharma has reached the target number of patients to be treated in its first clinical trial, Odyssée. The biotech is testing the efficacy of its drug candidate, MaaT001.3, using Autologous Fecal Microbiota Transfer on patients...
by admin | Jun 15, 2017 | Press Releases
Lyon (France), June 15, 2017. A few days after signing a strategic partnership for the treatment of intestinal dysbiosis by FMT (Fecal Microbiota Transfer), MaaT Pharma pursues its industrialization process with the CE marking of the first ever stool collection and...
by admin | Jun 8, 2017 | Press Releases
Lyon (France), June 8, 2017. Following their investment in MaaT Pharma a year ago, Biocodex is taking a further step with the French microbiotech[1] company, marking a turning point in the history of the European microbiota specialist. MaaT Pharma’s...
by admin | May 31, 2017 | Newsletter
EDITO Today more than ever microbiota is recognized to play a key on the individual’s health. Recent studies have shown the effectiveness of Fecal Microbiota Transfer (FMT) to modulate microbiota and address specific pathologies. While FMT remains the highest...
